NeoPharm has signed a letter of intent with Siro ClinPharm USA with regard to Siro's engagement to oversee a planned confirmatory Phase III trial for its drug product candidate Cintredekin Besudotox, for the treatment of patients suffering from recurrent glioblastoma
Alsius has signed a three-year contract with HealthTrust Purchasing Group, to provide intravascular temperature management products to the group purchasing organization's network of over 1,400 not-for-profit and for-profit acute care hospitals.
Urologix has reported long-term clinical results from a multi-center trial with the Urologix Cooled ThermoCath microwave catheter for treatment of benign prostatic hyperplasia, also known as enlarged prostate.
Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have reported preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of Relistor.
VistaGen Therapeutics has announced that Sanwa Kagaku Kenkyusho, an international pharmaceutical company headquartered in Nagoya, Japan, has selected to license three customized ES cell-based beta-islet differentiation assay systems developed under the agreement.
Tibion has signed a collaboration agreement with Stanford University's biomechanical engineering group to develop future applications of its bionic technology.
Derma Sciences has reached an agreement in principle with a major Canadian retail pharmacy chain, and expects a contract to be executed by both parties in the near future. The terms call for minimum purchases of $2 million each year
Ardea Biosciences has announced that its non-nucleoside reverse transcriptase inhibitor candidate, RDEA806, demonstrated no reproductive toxicity in preclinical studies.
Somaxon Pharmaceuticals has signed a $15 million secured loan agreement with Oxford Finance and Silicon Valley Bank and a committed equity financing facility with Kingsbridge Capital in which Kingsbridge has committed to provide up to $50 million of capital through
Epeius Biotechnologies has announced the positive results from an on-going US-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy.
Aveo Pharmaceuticals has announced that the US Patent and Trademark Office has granted patent covering the company's mammalian second site suppressor screen technology for identifying small molecule and antibody targets functionally relevant to cancer cell proliferation and survival.
China Biologic Products has received approval from the Bureau of Health in Guangxi Province to relocate its Fang Cheng plasma collection station to a more favorable location with a wider coverage area and to purchase excess clinical plasma from six
Clarient, a provider of anatomic pathology and molecular testing services, has announced that its senior vice president and CFO, Jim Agnello, will step down from that position.
NeoStem has announced a private placement financing in a total amount of $0.9 million, which includes a strategic investment from the New England Cryogenic Center.
